Enzon Pharmaceuticals Statistics
Total Valuation
ENZN has a market cap or net worth of 7.63 million. The enterprise value is 3.26 million.
| Market Cap | 7.63M |
| Enterprise Value | 3.26M |
Important Dates
The last earnings date was Friday, March 21, 2025.
| Earnings Date | Mar 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ENZN has 74.21 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 74.21M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 7.23% |
| Owned by Institutions (%) | 48.58% |
| Float | 30.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 293.91 |
| PB Ratio | 2.54 |
| P/TBV Ratio | 2.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.56 |
| EV / Sales | 125.33 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 28.10
| Current Ratio | 28.10 |
| Quick Ratio | 27.93 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 1.70% and return on invested capital (ROIC) is -1.81%.
| Return on Equity (ROE) | 1.70% |
| Return on Assets (ROA) | -1.75% |
| Return on Invested Capital (ROIC) | -1.81% |
| Return on Capital Employed (ROCE) | -2.92% |
| Revenue Per Employee | 26,000 |
| Profits Per Employee | -497,000 |
| Employee Count | 1 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +5.82% in the last 52 weeks. The beta is 0.26, so ENZN's price volatility has been lower than the market average.
| Beta (5Y) | 0.26 |
| 52-Week Price Change | +5.82% |
| 50-Day Moving Average | 0.12 |
| 200-Day Moving Average | 0.13 |
| Relative Strength Index (RSI) | 44.29 |
| Average Volume (20 Days) | 28,571 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.08 |
Income Statement
In the last 12 months, ENZN had revenue of 26,000 and -497,000 in losses. Loss per share was -0.01.
| Revenue | 26,000 |
| Gross Profit | 26,000 |
| Operating Income | -1.33M |
| Pretax Income | 1.13M |
| Net Income | -497,000 |
| EBITDA | n/a |
| EBIT | -1.33M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 46.86 million in cash and n/a in debt, giving a net cash position of 46.86 million or 0.63 per share.
| Cash & Cash Equivalents | 46.86M |
| Total Debt | n/a |
| Net Cash | 46.86M |
| Net Cash Per Share | 0.63 |
| Equity (Book Value) | 45.49M |
| Book Value Per Share | 0.04 |
| Working Capital | 45.47M |
Cash Flow
| Operating Cash Flow | 1.12M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 100.00%, with operating and profit margins of -5,103.85% and 2,992.31%.
| Gross Margin | 100.00% |
| Operating Margin | -5,103.85% |
| Pretax Margin | 4,326.92% |
| Profit Margin | 2,992.31% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ENZN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 163.88% |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -6.51% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ENZN has an Altman Z-Score of 2.07. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.07 |
| Piotroski F-Score | n/a |